KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however, recent data suggest that this independence may not be absolute. We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRASdriven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRAS
INTRODUCTION
Cancers of the lung account for more than 1.5 million deaths per annum worldwide, and 5-year survival rates remain between 10 and 15% in many developed countries (1) . The majority of lung cancers are classified as non-small cell (NSCLC), and adenocarcinoma is the most common histological subtype of NSCLC. Activating mutations in KRAS occur in a third of lung adenocarcinoma (LuAd) cases (2) . RAS proteins have historically proven to be elusive targets for selective inhibition, although the recent development of G12 mutant KRAS-selective tool compounds suggests that therapeutic targeting of KRAS may, in time, be possible (3, 4) . In the interim, there is a pressing need to develop alternative strategies for more effective treatment of KRAS-driven disease.
The ERBB family of receptor tyrosine kinases (RTKs) is composed of four members-EGFR (ERBB1), HER2 (ERBB2, NEU), ERBB3, and ERBB4-all of which can homo-or heterodimerize, and dimerization is required for signaling activity. ERBB dimers are activated upon binding a spectrum of soluble ligands including EGF, epiregulin (EREG), amphiregulin (AREG), and neuregulin (NRG), together forming a network for ERBB-driven signal transduction (5) . EGFR is a wellrecognized driver of LuAd, with genetic alterations present in up to 18% of cases (2) . ERBB2 and ERBB3 are highly expressed in embryonic lungs of humans and rodents, and expression of both persists into adulthood (6, 7) . Overexpression of ERBB2 in the absence of gene amplification is common in human LuAd (8, 9) , and functionality of ERBB2/ERBB3 heterodimers in NSCLC-derived cell lines was previously shown (10) . Amplification of any of the four ERBB RTKs is associated with poor prognosis in lung cancer (11) , and high expression of the promiscuous ERBB ligand EREG has previously been linked to disease progression and aggressive phenotypes in models of EGFR-and KRAS-driven lung cancer (12, 13) .
In a wild-type setting, ligand-activated signaling through ERBB RTKs activates KRAS (14) . Mutation of KRAS is generally thought to confer independence from upstream regulation, a view that is reinforced by the mutual exclusivity of activating mutations in KRAS and EGFR in LuAd, and by the failure of EGFR-selective inhibitors to show therapeutic benefit against KRAS-driven cancers (15, 16) . However, several recent results suggest that the independence of mutant KRAS from upstream signaling may not be absolute: In KRASmutant NSCLC cell lines, activation of phosphatidylinositol 3-kinase (PI3K) is contingent upon basal activity of wild-type insulin-like growth factor receptor (IGFR), establishing an important precedent for coordination of oncogenic and normal signal transduction (17) ; genetic deletion of EGFR was shown to suppress development of KRAS G12D -driven pancreatic ductal adenocarcinoma (18, 19) ; induced expression of ERBB2 and ERBB3 was found to underlie resistance of KRAS-mutant lung and colorectal cell lines to MEK (mitogen-activated protein kinase kinase) inhibition (20) . Strikingly, in the latter study, MEK inhibitorinduced ERBB2/3 expression was associated with recovery of extracellular signal-regulated kinase (ERK) phosphorylation downstream of KRAS, suggesting a surprising role for upstream signaling in sustaining pathway activity despite the presence of activated KRAS.
We therefore examined the requirement for ERBB activity in an inducible model of progressive autochthonous LuAd, driven by the combination of endogenously expressed KRAS G12D and modest overexpression of c-MYC. We present evidence that redundant signal transduction through multiple ERBB RTKs supports development and progression of mutant KRAS-driven lung tumors. Our data suggest that frontline use of multi-ERBB inhibitors may show clinical benefit in KRAS-driven LuAd.
RESULTS

ERBB activity is required for KRas
G12D
-driven lung tumor formation Induced expression of ERBB family RTKs is associated with resistance of KRAS-mutant NSCLC cell lines to MEK inhibition (20) . We therefore examined expression of ERBB RTKs and their ligands in microdissected early-stage lung tumors, using a CRE-inducible mouse model of autochthonous LuAd driven by KRAS G12D combined with modestly increased MYC (lsl-KRas
;Rosa26-lsl-MYC-henceforth KM), the latter expressed from the Rosa26 locus in amounts that alone fail to provoke a phenotype ( fig. S1A ). In tumor samples harvested 6 weeks after allele activation, we found strong expression of Erbb2 and Erbb3 mRNA, whereas Egfr was weakly expressed, and Erbb4 was not detected in tumors from two of four KM mice (Fig. 1A) . Multiple ERBB ligands were expressed, with Areg, Tgf, and Hbeg f showing strongest expression, whereas Egf, Ereg, Nrg3, and Nrg4 were also clearly detected (Fig. 1B) . The presence of both RTKs and multiple cognate ligands suggested that ERBB RTKs may actively signal in developing KRAS G12D -driven lung tumors. Lysates prepared directly from multiple individual tumors, harvested 6 weeks after induction and immunoblotted for phospho-ERBB RTKs, consistently showed readily detectable phospho-EGFR, phospho-ERBB2, and phospho-ERBB3, suggesting that these RTKs are active in developing KRAS G12D -driven lung tumors (Fig. 1C and fig. S1B ). To determine whether ERBB signaling functionally contributes to tumor development, we treated tumor-bearing mice acutely with a multi-ERBB inhibitor, neratinib (21) . Treatment of mice for 3 days with neratinib suppressed activity of ERBB RTKs, reduced tumor cell proliferation, and increased apoptosis, suggesting that ERBB activity promotes growth of KRAS G12D -driven tumors (Fig. 1, D to F) . Continuous daily treatment of mice from 2 weeks after allele induction almost completely suppressed the emergence of tumors, indicating that the combination of endogenously expressed KRAS G12D and constitutively expressed MYC requires input from ERBB RTKs to give rise to lung tumors (Fig. 1, G and H ). In contrast, daily erlotinib treatment failed to show the same effect, consistent with reports that EGFR inhibition in isolation is ineffective in KRASdriven lung cancer (15, 18) .
Progression of KRas-driven lung tumors is associated with increased ERBB network expression
The above analysis was performed on tumors at 5 to 6 weeks after adeno-CRE-mediated allele activation. At this time after induction, the lungs of all induced KM mice contained dozens of individual tumors that presented with uniform histology resembling human papillary adenocarcinoma in situ ( Fig. 2A, left panels) . A small minority of tumors (2 to 5%) also contained a second, more disorganized population with more aggressive histological features, including increased cytosolic and nuclear volume, prominent nucleoli, and increased morphological heterogeneity ( Fig. 2A, right panels) . IHC analysis revealed continuous expression of the type II pneumocyte marker SPC across both populations in individual tumors, suggesting that the second population represents the emergence of aggressive subclones ( fig. S1C ).
Progression of KRAS
G12D
-driven lung tumors to more aggressive disease is associated with a pronounced increase in ERK1/2 phosphorylation (22, 23) . Accordingly, IHC analysis of phospho-ERK (p-ERK) revealed much higher expression of p-ERK in these disorganized subclones compared with the rest of the same tumors and across the entire tumor population (Fig. 2, A and B) . By comparison, KM tumors harvested at 4 to 6 months after induction showed widespread expression of p-ERK, because these more aggressive subclones gradually came to predominate (Fig. 2B, bottom panel) . Moreover, KM metastases to the liver also show high amounts of epithelial p-ERK staining (Fig. 2, C to F) .
Increased p-ERK was previously shown to be associated with amplification of the mutant KRas locus in a KP lung cancer model, wherein KRAS G12D expression was combined with loss of functional p53 (24 fig. S1D ). Expression of KRas was modestly higher (less than twofold) in p-ERK High tumor regions, suggesting that locus amplification is not the underlying driver of progression in the KM model (Fig. 3A) . However, we detected a sharp increase in expression of promiscuous ERBB family ligands, Ereg and Areg, along with more modest increases in Hbegf and Tgf (Fig. 3,  B to D, and fig. S1E ). Increased expression of Ereg and Areg was previously reported to be associated with more aggressive tumors in an inducible model of KRAS-driven mammary cancer (25) and in human NSCLC cells enriched for metastatic behavior (26) . In situ hybridization (ISH) revealed a clear overlap between expression of Ereg, Areg, and extensive phosphorylation of ERK (by IHC) in tumor epithelium, confirming the RNA-seq data ( Fig. 3C and fig. S2, A and B) . The same phenotype of focal progression to p-ERK high accompanied by markedly increased Areg expression was also observed in primary lung tumors upon induction with a more lineage-restricted adeno-SPC-CRE (fig. S2, A and B), and in liver metastases after induction with the standard adeno-CMV-CRE ( Fig. 3D and fig. S2C ), arguing against the possibility that this phenotype might arise from inadvertent activation of the driver oncogenes in other lung-resident populations (27) . In addition, RNA-seq analysis revealed increased expression of Adam9 and Adam10 sheddases, which process membrane-bound ERBB ligands into their more potent soluble forms (28) ; increased expression of the signaling scaffold Iqgap2; and increased expression of LamC2, Fabp5, and Keratin19, all recently shown to enhance signaling through EGFR/ ERBB family RTKs (26, 29, 30) . Expression of Erbb2 and Erbb3 was not significantly changed in p-ERK High regions (Fig. 3, E and F) .
These data suggest an alternative route to increased RAS pathway signaling that does not require KRas amplification but rather involves increased activity of the ERBB network, defined here as consisting of ERBB ligands, RTKs, and RTK accessory molecules such as LamC2 and Fabp5. Notably, examination of The Cancer Genome Atlas (TCGA) LuAd data set via cBioPortal (31) revealed overexpression and/or amplification of one or more constituents of the ERBB network in the majority of KRAS-mutant human LuAd ( fig. S3 ).
ERBB signaling amplifies RAS pathway activity in KRAS-mutant human NSCLC cells
Combined inhibition of both EGFR and ERBB2 is required to prevent outgrowth of MEK inhibitor-resistant clones of human KRASmutant NSCLC cells; however, the effect of multi-ERBB inhibition on treatment-naïve cells was not previously explored (20) . Treatment of multiple KRAS-mutant human NSCLC lines with the multi-ERBB inhibitor neratinib suppressed proliferation in a dose-dependent manner (Fig. 4A ). In contrast, inhibition of EGFR in isolation showed little effect. Immunoblotting confirmed that the doses of neratinib used strongly suppressed activity of ERBB RTKs (Fig. 4B) . Consistent with previous reports that neratinib drives increased ERBB turnover (32), ERBB2 and ERBB3 protein expression was also reduced by neratinib in multiple cell lines. Despite the presence of G12 mutant KRAS in all such cells, neratinib consistently reduced p-ERK, whereas effects on AKT and signal transducer and activator of transcription 3 (STAT3) varied across the cell lines tested ( Fig. 4B and fig. S4A ). We therefore examined RAF binding as a direct measure of RAS signaling activity in A549 cells, which are homozygous for mutant KRAS. Acute ERBB inhibition reduced both total RAS:RAF and specific 
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KRAS:RAF binding by >50%, consistent with the observed partial reduction in p-ERK (Fig. 4C ). In addition, murine lung tumor cells carrying a spontaneously amplified KRas G12D allele also showed sensitivity to neratinib, albeit somewhat lower than that of cells carrying a single copy of the allele ( fig. S4B) , and RAS-less mouse embryonic fibroblasts (MEFs) reconstituted with G12D mutant KRAS were likewise sensitive to neratinib, albeit less so than those reconstituted with wild-type KRAS ( fig. S4, C and D) . Together, these results suggest that ERBB amplifies signaling through the core RAS→ERK module, even in cells with activating mutation of KRAS, whereas sensitivity to ERBB suppression is imparted through both mutant and wildtype KRAS.
To gain further mechanistic insight into the growth inhibitory effects of neratinib, we performed unbiased transcriptomic analysis after overnight treatment of three KRAS-mutant NSCLC cell lines. Metacore GeneGO pathway analysis revealed a remarkable degree of consistency across the three cell lines tested. Moreover, 18 of the 20 most highly modulated pathways associated with progression of murine KM tumors to p-ERK High disease were reciprocally modulated in the human cells upon neratinib treatment (Fig. 4D and table S1 ). In A all three cell lines, ERBB inhibition reduced expression of the same ERBB ligands that increased as KM tumors progressed to p-ERK High disease (Fig. 4E ). These findings indicate that ERBB activity establishes a feed-forward loop that sustains KRAS-mutant NSCLC proliferation in vitro and drives tumor progression in vivo at least in part by amplifying signaling through the core RAS-ERK module.
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ERBB inhibition enhances the potency of MEK inhibition in vitro and extends survival of mice with LuAd
With the exception of H358 cells, ERBB inhibition alone did not result in death of KRAS-mutant NSCLC cells in vitro; however, neratinib increased apoptosis induced by inhibition of MEK downstream of KRAS in multiple cell lines (Fig. 5A) . Substitution of neratinib with a second multi-ERBB inhibitor, afatinib, replicated the effects of neratinib, confirming the on-target specificity of the drug ( fig. S5A ). Moreover, both drugs combined with MEK inhibition to suppress colony formation (Fig. 5B) . Consistent with published results (20) , MEK inhibition alone increased expression of ERBB2 and ERBB3 in vitro, although the effect on ERBB2 phosphorylation was variable across the cell lines tested (Fig. 5C ). Cotreatment with neratinib suppressed both expression and activity of ERBB2 and ERBB3 while also suppressing EGFR activity (Fig. 5C) . Downstream of the RTKs, trametinib alone consistently suppressed expression of p-ERK and c-MYC, but increased phosphorylation of AKT and STAT3 (Fig. 5C ). Suppression of increased AKT phosphorylation by neratinib was clear only in H358 cells, but the drug combination failed to reduce STAT3 phosphorylation. The growth inhibitory effects of the drug combination in vitro thus better correlate with suppression of the core RAS-ERK-MYC pathway than with the activity of ancillary signaling pathways. The combination of MEK and multi-ERBB inhibition was previously shown to suppress the growth of subcutaneous NSCLC xenografts under continuous daily treatment (20) ; however, cell line xenografts have a poor track record of accurately predicting human patient responses. We therefore tested the therapeutic efficacy of transient inhibition of ERBB and/or MEK in our fully immunocompetent KM model of autochthonous LuAd. Tumors were induced in adult KM mice and allowed to develop for 6 weeks. The presence of an IRFP Cre-reporter allele (33) in a subset of such animals allowed us to confirm the presence of tumors by LI-COR Pearl fluorescence imaging before initiating therapy ( fig. S5B ). Mice were treated daily for 1 week with neratinib, alone or in combination with trametinib, and then left untreated to determine the effect on overall survival. Transient ERBB blockade alone showed little influence on overall survival, whereas MEK inhibition alone extended survival of KM mice. The combination of neratinib and trametinib further extended survival over that achieved by MEK inhibition alone (Fig. 5D) . Fluorescence imaging of IRFP-positive KM mice showed pronounced suppression of lung tumor growth in individual mice treated with combination therapy (fig. S5, B and C) . Immunoblotting of tumors from mice treated for 3 days with either drug alone or both combined confirmed the pathwayspecific effects of these inhibitors in vivo (Fig. 5E) . We conclude from these data that multi-ERBB inhibition may benefit LuAd patients with mutant KRAS-driven disease, if used in combination with other agents such as MEK inhibitors.
DISCUSSION
EGFR-selective inhibitors have failed to show clinical benefit in mutant KRAS-driven cancers. In contrast with targeted inhibition of EGFR in isolation, we show here that broad inhibition of the ERBB network, using the multi-ERBB inhibitor neratinib, almost completely suppresses formation of KRAS G12D -driven lung tumors and enhances the benefit of MEK inhibition in established tumors. We show that ERBB activity enhances signaling through the core RAS→ERK pathway, establishing a feed-forward loop that is associated with progression to invasion and metastasis. We also show that brief, transient inhibition of ERBB signaling enhances the therapeutic benefit of MEK inhibition in the autochthonous setting. Although this latter result is broadly supportive of the clinical implications of an earlier study showing that increased ERBB activity underlies resistance to MEK inhibition (20) , our data are fundamentally distinct in that we demonstrate a clear role for ERBB activity from the very outset of KRAS-driven tumor initiation, as opposed to in reaction to targeted inhibition of MEK.
Mechanistically, we show that nascent KRas
G12D
-driven lung tumors express multiple ERBB ligands and that production of these ligands increases markedly as tumors progress to more aggressive disease. In the cell culture setting, the release of these ligands drives autocrine signaling that supports the viability of cancer cells. In vivo, the release of such ligands into the extracellular milieu likely drives both autocrine and paracrine signal transduction in any local cell population that expresses ERBB RTKs. Hence, it is plausible to consider that some of the tumor-suppressive benefit of neratinib may derive from inhibition of ERBB signaling in such stromal populations. Nevertheless, our cell culture analysis argues that the primary effect of ERBB inhibition is autonomous to the tumor epithelium. Further work will be needed to determine whether paracrine activation of ERBB RTKs on attendant stromal cell populations plays any role in tumor maintenance or progression.
Previous work has revealed that threshold levels of KRAS signaling are required for tumor initiation and progression: In an inducible model of HRAS G12V overexpression in mammary glands, focal tumors arising spontaneously from nontransformed epithelium that expressed low amounts of the transgene exhibited a pronounced increase in expression of the HRas G12V transgene and of multiple ERBB ligands, including Ereg, Tgf, and Hbegf, again suggestive of feedforward signal amplification (25) . More recently, this same "activity threshold" principle was shown to apply to ERK signaling as the key oncogenic effector pathway of KRAS in the lung (34) . Through pharmacological enhancement of ERK activity, this study showed that different airway cell types require distinct amounts of ERK signaling for oncogenic transformation by mutant KRAS, and that a second, higher, threshold signal was needed for progression to carcinoma. The existence of this higher threshold in KRAS-driven LuAd was already clear from the pronounced increase in ERK phosphorylation associated with tumor progression (25) , which, in the KP model, is driven by spontaneous amplification of the G12D mutated allele (24) . Our data suggest that ratcheting up ERBB signal transduction provides an alternative route to RAS pathway signal amplification, independent of KRAS gene amplification. It is important to note that, from the human data, there does not appear to be a preferred mechanism of ERBB signal enhancement-overexpression of ligands, amplification of RTKs, and/or accessory molecules could all plausibly achieve the same effect. What is clear from these data is that the potential to increase ERBB signaling appears to be widespread in KRASmutant human LuAd.
Perhaps the most surprising observation is that endogenously expressed KRAS G12D requires basal signaling from ERBB RTKs to initiate lung tumors, even when accompanied by MYC overexpression. We previously showed that expression from the Rosa26 locus is refractory to growth factor signaling (35) ; thus, the requirement for ERBB activity does not reflect an artificial need for ERBB to sustain expression of the MYC transgene, whereas the observed effects on total MYC expression likely reflect the influence of RAS signaling on MYC protein stability (36) . Instead, these data suggest that G12 mutant KRAS requires a push from upstream RTKs to breach the initial threshold needed for tumor initiation. Supporting this hypothesis, it was recently shown that G12 mutant KRAS, although no longer responsive to RASGAPs [guanosine triphosphatase (GTPase)-activating proteins], does retain some level of intrinsic GTPase activity and thus cycles slowly between on and off states (4), opening the possibility for upstream signaling to influence activity, either directly or by promoting activity of RAS guanonucleotide exchange factors (GEFs). Alternatively, tonic signal transduction through wild-type RAS isoforms may need to combine with that from mutant KRAS to likewise breach the threshold for transformation (37) . Our data presently do not distinguish between these possibilities, and they may not be mutually exclusive.
In the course of preparing this manuscript, we became aware of an independent study that strongly complements our observations and underscores our conclusions: The work by Moll and colleagues similarly demonstrates a requirement for ERBB signaling to support progression of KRAS G12D -driven lung cancer in vivo (38) . Their study used an independent pan-ERBB inhibitor, afatinib, in the context of both KRAS G12D -only and KRAS G12D ;p53 Fl/Fl -driven tumor models. The strik ing similarities in the two studies attest to the on-target specificity of the two drugs used while also showing that the effects are independent of the genetic strategy used to accelerate KRAS-driven disease and are therefore likely to have broader potential application.
Activating mutations in KRAS are currently considered grounds for exclusion from clinical treatment with EGFR/ERBB inhibitors, and single-agent trials of the same drugs have only demonstrated efficacy in patient cohorts with activating mutations in EGFR or ERBB amplification (39) . Our data concur that multi-ERBB inhibitors are unlikely to benefit KRAS-driven cancer patients if used in isolation. However, we show here the potential for such drugs to sensitize autochthonous KRAS-driven tumors to additional therapeutic agents, in this case to the MEK inhibitor trametinib. Our data argue that clinical use of multi-ERBB inhibitors as part of an inhibitor cocktail to treat KRAS-driven LuAd deserves reexamination.
MATERIALS AND METHODS
Study design
Rationale for the project was to investigate the mechanistic basis of tumor progression in early-stage KRAS-driven lung cancer. Unbiased RNA-seq analysis identified increased expression of the ERBB network, prompting further mechanistic investigation. All mice were asymptomatic at the date of treatment initiation and were allocated to treatment groups randomly. For survival benefit analysis, the absence of previous data precluded a precise power calculation: Sample sizes were therefore estimated according to Lehr's quick formula at 80% power {n=16(c.v.)2(ln[r.m.])2}, assuming a ratio of the means of 0.2 and a coefficient of variation of 0.3. For all other analyses, sample sizes were determined in accordance with the 3Rs. Animals were treated by facility staff without knowledge of anticipated outcomes. Humane end points were predefined as impaired breathing and/or hunching with 10% or more weight loss. Histology, IHC, and ISH were performed blindly by the Beatson Institute histology core facility and were scored without reference to genotype or treatment group. Reporting is consistent with the ARRIVE guidelines. In vitro experiments were all performed on three separate occasions, except where noted. In vitro analyses were not blinded. mice were generated as previously described (35) with the ATG-initiated human c-MYC (MYC2) complementary DNA (cDNA), devoid of 5′ and 3′ untranslated regions, replacing the MYC-estrogen receptor ligandbinding domain fusion cDNA. Targeted insertion into the Rosa26 locus was confirmed by Southern blotting, and genotyping was initially performed with the following primers: (i) CCCAAAGTCGCTCT-GAGTTG (common), (ii) GCGAAGAGTTTGTCCTCAACC (targeted locus), and (iii) GGAGCGGGAGAAATGGATATGA (wild-type locus). All genotyping was subsequently performed by TransnetYX Inc. Detailed in vivo procedures are provided in the Supplementary Materials along with IHC, laser-capture microdissection, and RNAseq methodology.
Genetically engineered mice and mouse procedures
Cell culture and related assays
Human lung cancer cell lines (A549, H2009, and H358) were validated in-house and grown in RPMI 1640 with 10% fetal bovine serum (FBS) and penicillin (100 U/ml)/streptomycin (100 g/ml). RAS-less MEFs reconstituted with wild-type or mutant KRAS isoforms were provided by the NCI RAS Initiative, Frederick National Laboratory for Cancer Research (Frederick, MD) and were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS and penicillin (100 U/ml)/ streptomycin (100 g/ml). 
Statistical analysis
Raw data obtained from quantitative real-time polymerase chain reaction, fluorescence-activated cell sorting, and IncuCyte assays were copied into Excel (Microsoft) or Prism (GraphPad) spreadsheets. All mean, SD, and SEM values of biological replicates were calculated using the calculator function. Graphical representation of such data was also produced in Excel or in Prism. Statistical significance for pairwise data was determined by Student's t test. For multiple comparisons, ANOVA was used with a post hoc Tukey test. *P < 0.05, **P < 0.01, and ***P < 0.001. For Kaplan-Meier plots, log-rank P values are presented.
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